Donate Today Log In

Clinical Department · Precision Medicine

Cancer Care Through
Precision Oncology

Tumor Profiling · Genomics · Immuno-Oncology · Liquid Biopsy · Metabolomics · Survivorship

Molecular

Tumor Intelligence

Multi

Omic Data

100%

Patient-Centered

Board

Certified Standard

Department Overview

Pre·ci·sion
On·col·o·gy

/ ˈpreSHən äNGˈkäləjē / · noun

noun · clinical oncology

The application of molecular tumor profiling, liquid biopsy, and multi-omic intelligence to individualize cancer diagnosis, treatment selection, and therapeutic monitoring — moving beyond histology and staging to the genomic and immune drivers of each patient's malignancy.

Origin

From Latin praecisio (exactness) + Greek onkos (mass, tumor) + -logia (study of). Precision oncology crystallized as a clinical discipline following the landmark 2006 cancer genome sequencing studies and the clinical validation of targeted therapies — demonstrating that tumor biology, not organ of origin, should govern treatment decisions.

The Precision Oncology Department at the American Board of Precision Medicine trains clinicians to navigate cancer at the molecular level — integrating comprehensive genomic profiling, tumor mutational burden, microsatellite instability, liquid biopsy ctDNA analysis, and immune microenvironment characterization into a unified framework for individualized cancer care.

From actionable driver mutation identification and predictive biomarker-guided immunotherapy selection to clonal evolution tracking and resistance mechanism analysis, this department equips physicians with the oncogenomic fluency to match each patient's tumor to the most precisely targeted intervention — and to monitor treatment response at the molecular level in real time.

Cancer is not one disease — it is thousands of molecularly distinct diseases sharing a common phenotype of uncontrolled growth. At ABOPM, Precision Oncology provides the genomic and immune framework to treat each malignancy — and each patient — as the singular biological event it truly is.

500+

Actionable Mutations

ctDNA

Liquid Biopsy

Multi

Omic Tumor Profiling

Precision Oncology Department · ABOPM

Where Molecular Science Meets
Cancer Care

The Precision Oncology Department at ABOPM is dedicated to transforming cancer care through molecular insight — training physicians to integrate tumor genomics, liquid biopsy, immunoprofiling, and targeted therapeutics into individualized treatment strategies that move beyond population averages and treat each cancer as the unique disease it is.

Tumor Genomics

Advancing clinical application of somatic mutation profiling, copy number analysis, gene fusion detection, and tumor mutational burden assessment — equipping oncologists to match each patient's cancer molecular signature to the most effective targeted or immunotherapy strategy.

Clinical Translation

Bridging oncology research and patient care — developing board-certified frameworks for biomarker-driven treatment selection, resistance mechanism interpretation, liquid biopsy monitoring, and adaptive precision therapy across solid tumors and hematologic malignancies.

Physician Education

Building the next generation of precision oncologists through rigorous board standards, interdisciplinary training, and collaboration across medical oncology, radiation oncology, surgical oncology, pathology, genomics, and translational cancer research.

"Every cancer is a molecular fingerprint. The Precision Oncology Department at ABOPM trains physicians to read that fingerprint — translating tumor genomics, immune profiling, and resistance biology into treatment decisions that are as individual as the patients who need them."

American Board of Precision Medicine · Precision Oncology Department

Become a Member → Support Our Mission → Get Involved →

Precision Oncology Department · ABOPM

Translating Tumor Genomics
Into Transformative Cancer Care

No two cancers are the same — even within the same histological type. Every tumor carries a unique molecular fingerprint of somatic mutations, copy number alterations, gene fusions, and immune interactions that determines how it will behave and how it will respond to treatment. Reading that fingerprint and acting on it is not the future of oncology — it is the present standard every cancer patient deserves.

Precision oncology equips clinicians to move beyond histology-based protocols and into molecularly individualized cancer care — integrating tumor genomic profiling, liquid biopsy, immunoprofiling, and resistance mechanism analysis to select, sequence, and adapt therapies with a level of precision that population-based guidelines cannot provide.

By mastering precision oncology, clinicians gain the power to:

01

Read the Tumor's Molecular Fingerprint

Move beyond histology and tumor site to interpret comprehensive genomic profiles — identifying the actionable somatic mutations, copy number alterations, gene fusions, and mutational signatures that define each patient's cancer and guide targeted treatment selection.

02

Deploy Liquid Biopsy with Precision

Use circulating tumor DNA and cell-free DNA analysis to detect minimal residual disease, monitor treatment response in real time, identify emerging resistance mutations early, and adapt therapeutic strategy before clinical progression becomes visible on imaging.

03

Interpret the Tumor Immune Microenvironment

Apply tumor mutational burden, microsatellite instability, PD-L1 expression, and immune cell profiling to identify which patients will respond to immunotherapy — and which require combination strategies, alternative checkpoints, or immune modulation.

04

Anticipate and Overcome Resistance

Understand the molecular mechanisms of acquired and intrinsic resistance — mapping escape pathways, identifying bypass signaling, and designing adaptive treatment sequences that stay ahead of tumor evolution and maintain durable disease control.

05

Lead Precision Oncology at Your Institution

Become the molecular tumor board leader, precision oncology program director, and clinical genomics authority your institution needs — the oncologist who translates complex genomic data into actionable treatment decisions that change outcomes for every patient.

Why Precision Oncology Certification Is Non-Negotiable

Every tumor has a molecular story. The question is, are you trained to read it?

Patient Outcomes

Molecularly matched therapies consistently outperform empiric chemotherapy in response rates, progression-free survival, and quality of life — delivering measurably better outcomes for patients whose cancers are treated with genomic precision rather than population averages.

Future-Ready Practice

Comprehensive genomic profiling, ctDNA monitoring, and AI-driven treatment matching are becoming standard of care across solid tumors and hematologic malignancies — oncologists board-certified in precision oncology will lead this transformation.

Clinical Authority

Board certification in precision oncology marks you as the molecular tumor board leader and genomic oncology authority — a clinician capable of guiding the most complex treatment decisions and driving institutional precision cancer programs.

Cross-Tumor Impact

Precision oncology principles apply across every tumor type — solid tumors, hematologic malignancies, rare cancers, and pediatric oncology — giving you a universal molecular framework to deliver individualized cancer care regardless of histology or site of origin.

Active research areas driving precision oncology forward:

01

Comprehensive Genomic Profiling

Advancing clinical application of whole-exome and whole-genome tumor sequencing, somatic mutation profiling, copy number analysis, and gene fusion detection — building the evidence base for genomically matched therapy selection across solid tumors and hematologic malignancies at every stage of disease.

02

Liquid Biopsy & ctDNA Science

Developing and validating circulating tumor DNA assays for minimal residual disease detection, treatment response monitoring, early recurrence identification, and resistance mutation tracking — establishing the clinical frameworks that translate liquid biopsy data into actionable, real-time oncology decisions.

03

Tumor Immune Microenvironment

Characterizing the cellular and molecular composition of the tumor immune microenvironment — mapping TMB, MSI status, PD-L1 expression, TIL infiltration, and immune evasion mechanisms to identify which patients will respond to immunotherapy and which require combination or alternative immune strategies.

04

Resistance Mechanism Analysis

Mapping the molecular pathways of acquired and intrinsic therapy resistance — identifying bypass signaling, secondary mutations, phenotypic switching, and clonal evolution dynamics to design adaptive treatment sequences that anticipate tumor escape and maintain durable disease control.

05

Tumor Agnostic & Basket Trial Research

Building the clinical evidence and board-certified frameworks for biomarker-driven, histology-agnostic treatment strategies — advancing the science of treating cancers by their molecular signature rather than their tissue of origin, across every tumor type where actionable alterations are found.

Precision Oncology Research · ABOPM

Pushing the Frontier of Molecular Cancer Medicine

The precision oncology revolution is not a future event — it is rewriting cancer care today. Comprehensive genomic profiling, liquid biopsy monitoring, immune microenvironment characterization, and resistance mechanism mapping are actively transforming how every cancer is diagnosed, classified, and treated at the molecular level.

The ABOPM Precision Oncology Department positions clinicians at the center of this transformation — equipping them with the tumor genomics literacy, molecular diagnostic frameworks, and board-certified credentials to lead precision cancer care in any oncology setting.

$132B

Precision oncology market projected by 2030

3×

Higher response rates with genomically matched therapy

50%

Of advanced cancers carry an actionable genomic alteration

Explore Blog Topics → Read clinical insights, case studies & precision oncology updates on our blog

Precision Oncology Department · ABOPM

Meet Our Leadership

Director of Precision Oncology

Director

Precision Oncology

Director of Precision Oncology Molecular Pathology Precision Diagnostics

Emre Baser, MD

Precision Medicine & Oncology Leader · Molecular Pathology & Diagnostics Specialist · International Clinician-Researcher

"Leading at the intersection of precision medicine, oncology, molecular pathology, and diagnostics — empowering patients and colleagues through innovation, knowledge-sharing, and a commitment to patient-centered care."

Dr. Emre Baser leads initiatives at the intersection of precision medicine, oncology, molecular pathology, and diagnostics. Trained in medicine at Cumhuriyet University (Türkiye) and Maastricht University (Netherlands), with clinical experience at Justus Liebig University (Germany), he brings both deep clinical expertise and a passionate research vision to his leadership role at ABOPM.

Dr. Baser has spearheaded pioneering research projects in collaboration with academic institutions, research foundations, and pharmaceutical companies, while simultaneously leading educational initiatives in precision oncology. His work bridges translational cancer science and frontline clinical application — advancing the frameworks that allow oncologists to act on molecular tumor data with precision and confidence.

Dedicated to both innovation and patient-centered education, Dr. Baser empowers patients and colleagues through knowledge-sharing and mentorship. Beyond medicine, he values time with family and is an avid reader who draws on diverse perspectives to enrich his clinical and scientific work.

3

Countries of Clinical Training

Pharma

Industry Research Collaborations

Multi

Institutional Research Projects

Connect on LinkedIn

Faculty Members

Our faculty roster is growing — announcements coming soon.

Coming Soon

Faculty position open

Coming Soon

Faculty position open

Coming Soon

Faculty position open

Coming Soon

Faculty position open

Think you're the right fit for a faculty position?

Get Involved →

Genomics Department · ABOPM

Shaping the Future
of Precision Medicine

As precision medicine continues to evolve, genomics will play an increasingly central role in redefining how disease is understood, predicted, and treated at the molecular level.

The Genomics Department at ABOPM remains committed to advancing this field through scientific leadership, clinical innovation, and collaborative discovery. Together with our global community of physicians and researchers, we are helping shape the future of next-generation healthcare.

Explore Certification → Get Involved

Featured Insights

Insights Shaping
Precision Medicine

Explore ABOPM perspectives on genomics, multi-omics, systems thinking, clinical innovation, and the future of physician leadership in precision medicine.

Multi-Omics Clinical Innovation Precision Prevention Physician Leadership

Liquid Biopsy and Early Cancer Detection: Promise and Limitations

Liquid biopsy is transforming cancer detection through minimally invasive genomic testing, offering new opportunities for earlier diagnosis and monitoring. ...more

Precision Oncology

June 05, 2026•9 min read

Polygenic Risk Scores and the Genomic Data Gap: Promise, Limitations, and Equity in Precision Medicine

Polygenic risk scores may transform disease prediction, but gaps in genomic diversity continue to limit equity, accuracy, and access in precision medicine across global populations. ...more

Population Precision

May 26, 2026•9 min read

Artificial Intelligence in Precision Medicine

Artificial intelligence is reshaping precision medicine by improving diagnostics, predicting treatment response, and enabling more personalized, data-driven healthcare strategies. ...more

On the Frontier

May 20, 2026•9 min read